MULN vs NVAX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MULN is a Buy and NVAX is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MULN’s FA Score shows that 0 FA rating(s) are green whileNVAX’s FA Score has 0 green FA rating(s).
- MULN’s FA Score: 0 green, 5 red.
- NVAX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MULN’s TA Score shows that 3 TA indicator(s) are bullish while NVAX’s TA Score has 5 bullish TA indicator(s).
- MULN’s TA Score: 3 bullish, 3 bearish.
- NVAX’s TA Score: 5 bullish, 5 bearish.
Price Growth
MULN (@Motor Vehicles) experienced а +6.58% price change this week, while NVAX (@Biotechnology) price change was -1.48% for the same time period.
The average weekly price growth across all stocks in the @Motor Vehicles industry was +3.72%. For the same industry, the average monthly price growth was +5.84%, and the average quarterly price growth was -11.43%.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.
Reported Earning Dates
MULN is expected to report earnings on May 31, 2023.
NVAX is expected to report earnings on Mar 04, 2025.
Industries' Descriptions
@Motor Vehicles (+3.72% weekly)Automobiles continue to be arguably the most popular form of passenger travel in the U.S., and major automobile makers have revenues and market capitalizations running into multi-billions. In recent years, the industry has been experiencing some path-breaking innovations like electric vehicles and self-driving technology. While there are long-standing companies like General Motors, Ford, and Toyota Motors operating in this space, there are also emerging/rapidly growing players like Tesla – which has had a major role in the growing popularity of the electric vehicle market. With technological advancements taking steam in the auto space, we’ve also witnessed collaborations (or talks of potential partnerships) of carmakers with tech behemoths like Google’s subsidiary, Waymo.
@Biotechnology (+0.91% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| MULN | NVAX | MULN / NVAX | |
| Capitalization | 34.1M | 2.13B | 2% |
| EBITDA | -686.05M | -228.25M | 301% |
| Gain YTD | -99.830 | 108.333 | -92% |
| P/E Ratio | 0.00 | N/A | - |
| Revenue | 366K | 560M | 0% |
| Total Cash | 81.5M | 1.05B | 8% |
| Total Debt | 19M | 233M | 8% |
MULN | NVAX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 2 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 51 Fair valued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 97 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 99 | 42 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MULN's Valuation (51) in the null industry is somewhat better than the same rating for NVAX (88) in the Biotechnology industry. This means that MULN’s stock grew somewhat faster than NVAX’s over the last 12 months.
NVAX's Profit vs Risk Rating (97) in the Biotechnology industry is in the same range as MULN (100) in the null industry. This means that NVAX’s stock grew similarly to MULN’s over the last 12 months.
NVAX's SMR Rating (100) in the Biotechnology industry is in the same range as MULN (100) in the null industry. This means that NVAX’s stock grew similarly to MULN’s over the last 12 months.
NVAX's Price Growth Rating (42) in the Biotechnology industry is somewhat better than the same rating for MULN (99) in the null industry. This means that NVAX’s stock grew somewhat faster than MULN’s over the last 12 months.
NVAX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MULN (100) in the null industry. This means that NVAX’s stock grew similarly to MULN’s over the last 12 months.
| MULN | NVAX | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 86% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 87% |
| MACD ODDS (%) | N/A | 2 days ago 89% |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 89% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 87% |
| Advances ODDS (%) | 7 days ago 83% | 28 days ago 84% |
| Declines ODDS (%) | 14 days ago 90% | 2 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 82% |
NVAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with THRD. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then THRD could also see price increases.
| Ticker / NAME | Correlation To NVAX | 1D Price Change % | ||
|---|---|---|---|---|
| NVAX | 100% | -1.19% | ||
| THRD - NVAX | 42% Loosely correlated | -3.21% | ||
| ADMA - NVAX | 39% Loosely correlated | +0.13% | ||
| ITOS - NVAX | 38% Loosely correlated | -1.56% | ||
| EDIT - NVAX | 33% Poorly correlated | -2.43% | ||
| RXRX - NVAX | 32% Poorly correlated | -4.24% | ||
More | ||||